Our Mission

Established in 2013, the Oklahoma Clinical and Translational Science Institute serves as a catalyst for clinical and translational research that improves health and healthcare for underserved and underrepresented populations, to provide training and infrastructure to help junior investigators to launch independent research careers, and to expand the opportunities of IDeA states and Oklahoma communities to participate in research that improves the health of our residents. 

Oklahoma Shared Clinical and Translational Resources

OSCTR is Oklahoma's NIH-funded IDeA-CTR that provides resources, information, and training to help individuals or communities involved in performing clinical and translational research in the state

Oklahoma Primary Healthcare Improvement Cooperative

 

OPHIC is the implementation science arm of a statewide network to help improve healthcare delivery assisting primary care practices to adopt evidence-based best practices for the care of their patients.

OCTSI Clinical Research Unit

​​

The OCTSI CRU assists medical providers to identify and conduct clinical research opportunities in Oklahoma.

​

 

 

 

 

 

OCTSI on the Radio

Submitted by Anonymous (not verified) on

OCAST Oklahoma Innovations will air this Saturday and Sunday on the stations below. It will be available on the OCAST website www.ok.gov/ocast/News_Media/Radio_Show , along with a transcript, on Monday. 

The week's program features OUHSC research leaders discussing science and medicine in Oklahoma. Dr. Judith James, the Principal Investigator of the Oklahoma Shared Clinical and Translational Resources discusses the Oklahoma Clinical and Translational Science Institute and our projects. 

Subscribe to News

Recent Publications

Impact of COVID-19 Diagnosis on Weight Trajectories of Children in the US National COVID Cohort Collaborative

medRxiv [Preprint]. 2025 Jan 5:2025.01.03.25319927. doi: 10.1101/2025.01.03.25319927.

ABSTRACT

BACKGROUND: The COVID-19 pandemic has exacerbated the obesity epidemic, with both adults and children demonstrating rapid weight gain during the pandemic. However, the impact of having a COVID-19 diagnosis on this trend is not known.

Oxidized high-density lipoprotein and low-density lipoprotein in adolescents with obesity and metabolic dysfunction-associated steatotic liver disease

Pediatr Obes. 2024 Dec 16:e13194. doi: 10.1111/ijpo.13194. Online ahead of print.

ABSTRACT

BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly common in the pediatric population and may increase risk for developing cardiovascular disease (CVD) in people with MASLD. Oxidized high-density lipoprotein (oxHDL) and oxidized low-density lipoprotein (oxLDL) are modified, pro-atherosclerotic lipoproteins that are increased in adults with MASLD and CVD but have not been reported in adolescents with MASLD.

Upcoming Events

Ethical Tribal Engagement Series

Media

Copyright © 2025 The Board of Regents of the University of Oklahoma. All rights reserved
Disclaimer | Copyright | Equal Opportunity Employer

Built and Managed by the OCTSI. Base theme by Zymphonies